Classifications: anticoagulants; antiplatelet agent; Therapeutic: anticoagulants; antiplatelet agent
Pregnancy Category: B
75 mg tablets
Inhibits platelet aggregation by selectively preventing the binding of adenosine diphosphate to its platelet receptor. It
is an analog of ticlopidine. The drug's effect on the adenosine diphosphate receptor of a platelet is irreversible.
Clopidogrel prolongs bleeding time, thereby reducing atherosclerotic events in high-risk patients.
Acute coronary syndrome (ST or non-ST elevations). Secondary prevention of MI, stroke, and vascular death in patients with
recent MI, stroke, unstable angina or established peripheral arterial disease.
Reduction of restenosis after stent placement.
Hypersensitivity to clopidogrel; intracranial hemorrhage, peptic ulcer, or any other active pathologic bleeding. Discontinue
clopidogrel 7 d before surgery and during lactation. Safety and efficacy not established in children.
Concurrent use with drugs that might induce gastrointestinal bleeding; GI bleeding, peptic ulcer disease; hepatic impairment
(moderate to severe); severe renal impairment; patients at risk for increased bleeding; pregnancy (category B).
Route & Dosage
Adult: PO 75 mg q.d.
Acute Coronary Syndrome (Non-ST Elevation)
Adult: PO 300 mg loading dose then 75 mg q.d. (use with aspirin)
- Do not administer to persons with active pathologic bleeding.
- Discontinue drug 7 d prior to surgery.
- Store at 15°30° C (59°86° F) in tightly closed container and protect from light.
Adverse Effects (≥1%) Body as a Whole:
, pain, arthralgia
, back pain. CV:
Chest pain, edema, hypertension, thrombocytopenic purpura. GI:
Abdominal pain, dyspepsia, diarrhea
, nausea, hypercholesterolemia. Hematologic:
Thrombotic thrombocytopenic purpura, epistaxis. CNS:
Headache, dizziness, depression
, rhinitis, bronchitis
, cough. Skin:
Interactions Drug: nsaids
may increase risk of bleeding events. Herbal: Garlic, ginger, ginkgo
may increase risk of bleeding.
Rapidly absorbed from GI tract. Onset:
2 h; reaches steady state in 37 d. Distribution:
9498% protein bound. Metabolism:
Rapidly hydrolyzed in plasma
to active metabolite
50% in urine and 50% in feces. Half-Life:
Assessment & Drug Effects
- Carefully monitor for and immediately report S&S of GI bleeding, especially when coadministered with NSAIDs, aspirin, heparin, or warfarin.
- Lab tests: Periodic platelet count and lipid profile.
- Evaluate patients with unexplained fever or infection for myelotoxicity.
Patient & Family Education
- Report promptly any unusual bleeding (e.g., black, tarry stools).
- Avoid chronic aspirin or NSAID use unless approved by physician.